Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Phase II Study of AC-201 in Patients With Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Diacerein (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors TWi Pharmaceuticals
- 25 Jun 2013 Results presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
- 06 Aug 2012 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met.
- 06 Aug 2012 Status changed from active, no longer recruiting to completed, according to a TWi Pharmaceuticals media release.